These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9307673)

  • 1. Saquinavir in the management of HIV infection.
    Moyle G
    Br J Hosp Med; 1997 Jun 4-17; 57(11):560-4. PubMed ID: 9307673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 4. Practical issues regarding the use of antiretroviral therapy for HIV infection.
    Deeks SG
    West J Med; 1998 Feb; 168(2):133-9. PubMed ID: 9499754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors.
    Vella S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy in the management of HIV infection.
    Vella S; Franca Pirillo M
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():23-6. PubMed ID: 9003571
    [No Abstract]   [Full Text] [Related]  

  • 7. [HIV protease inhibitors. A new drug class in antiretroviral therapy].
    Mauss S; Seidlitz B; Jablonowski H; Häussinger D
    Dtsch Med Wochenschr; 1996 Nov; 121(44):1369-74. PubMed ID: 8964223
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational approaches to resistance: using saquinavir.
    Boucher C
    AIDS; 1996 Nov; 10 Suppl 1():S15-9. PubMed ID: 8970671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
    Rockstroh JK; Altfeld M; Kupfer B; Kaiser R; Fätkenheuer G; Salzberger B; Schneweis KE; Spengler U
    Eur J Med Res; 1999 Jul; 4(7):271-4. PubMed ID: 10425264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The combination of saquinavir and ddC ensures longer survival].
    Hoof T
    Dtsch Med Wochenschr; 1996 Sep; 121(37):A30. PubMed ID: 8925721
    [No Abstract]   [Full Text] [Related]  

  • 14. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
    Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease inhibitors: resistance, resistance, resistance.
    Gilden D; Falkenberg J; Torres G
    GMHC Treat Issues; 1997 Feb; 11(2):5-10. PubMed ID: 11364108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data in from first head-to-head protease inhibitor.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy.
    Moyle GJ; Sadler M; Buss N
    Clin Infect Dis; 1999 Feb; 28(2):403-4. PubMed ID: 10064262
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiretroviral update: recent advances expand options for patients with HIV.
    Santhanam H; Goins M
    Adv Nurse Pract; 2004 Nov; 12(11):53-4, 56. PubMed ID: 15559568
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of HIV infection in Nigeria with zalcitabine in combination with saquinavir mesylate: preliminary findings.
    Akinsete I; Njoku OS; Okanny CC; Chukwuani CM; Akanmu AS;
    West Afr J Med; 2000; 19(4):265-8. PubMed ID: 11391837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV protease inhibitors].
    Rubio R; Romeu J; Viciana P; Redondo C
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():10-4. PubMed ID: 9053020
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.